Ribonuclease inhibitor human

Inhibits ribonucleases during transcription and translation experiments

MDL number:
Pricing and availability is not currently available.

Quality Level


for molecular biology


buffered aqueous solution

mol wt

~50 kDa


30,000-50,000 units/mL

shipped in

dry ice

storage temp.


Looking for similar products? Visit Product Comparison Guide

General description

Ribonuclease inhibitor works to inhibit RNase activity by forming a tight, non-covalent 1:1 complex. It is human placenta. It inhibits RNases A, B, and C. It will not inhibit RNases H, 1, T1, S1 Nuclease, SP6, T7 RNA Polymerase, T3 RNA Polymerase, AMV Reverse Transcriptase, M-MLV Reverse Transcriptase, or Taq Polymerase. The inhibitor can be removed by phenol extraction or by heating to 65°C for 10 minutes.


Useful for in vitro inhibition of ribonucleases, including procedures like cDNA synthesis, RT-PCR, and in vitro transcription and translation.
Suitable for use in
  • in vitro inhibition of ribonucleases
  • cDNA synthesis
  • RT-PCR
  • in vitro transcription and translation

Biochem/physiol Actions

Inhibits RNase by forming a tight, non-covalent 1:1 complex. Also inhibits angiogenin, a neovascularization promoter which is homologous with RNase A.


Ribonuclease Inhibitor is provided as a solution in 20 mM HEPES-KOH( pH 7.6), 50 mM KCl, 8 mM DTT and 50% glycerol.

Other Notes

This inhibitor of RNase activity is isolated from human placenta and supplied as a buffered aqueous glycerol solution.
Solution in 50% glycerol, 20 mM HEPES-KOH, pH 7.6, 50 mM KCl and 8 mM DTT

Unit Definition

One unit will reduce the activity of 5 ng of ribonuclease A by 50% in a cytidine 2′:3′-cyclic monophosphate system.

Physical form

Solution in 50% glycerol, 20 mM HEPES-KOH, pH 7.6, 50 mM KCl and 8 mM DTT

Personal Protective Equipment

dust mask type N95 (US),Eyeshields,Gloves


NONH for all modes of transport

WGK Germany


Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis
Certificate of Origin
Sabahattin Kaymakoglu et al.
Antimicrobial agents and chemotherapy, 49(3), 1135-1138 (2005-02-25)
The success of alpha interferon (IFN-alpha) monotherapy for the treatment of chronic hepatitis D is very limited. In this study, the efficacy of IFN-alpha and ribavirin combination therapy for chronic hepatitis D was investigated. Nineteen patients (15 males; mean age...
Ribonuclease inhibitor from human placenta: interaction with derivatives of ribonuclease A.
P Blackburn et al.
The Journal of biological chemistry, 254(24), 12488-12493 (1979-12-25)
Michal Mikula et al.
The Journal of biological chemistry, 286(11), 9763-9775 (2011-01-15)
Components of the ERK cascade are recruited to genes, but it remains unknown how they are regulated at these sites. The RNA-binding protein heterogeneous nuclear ribonucleoprotein (hnRNP) K interacts with kinases and is found along genes including the mitogen-inducible early...
Malia Su-Qin Murphy et al.
American journal of obstetrics and gynecology, 213(3), 367-367 (2015-05-20)
Preeclampsia (PE) is a hypertensive disorder of pregnancy characterized by widespread maternal endothelial dysfunction. Although clinical signs subside following delivery, long-term risks associated with PE include hypertension, stroke, and cardiovascular disease. MicroRNAs (miRNAs) are emerging as critical regulators of biological...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.